Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
seizures
Biotech
Praxis epilepsy drug reduces seizures in phase 2 trial
Participants who received relutrigine saw an average 46% reduction in their seizures during the double-blind part of the study.
James Waldron
Sep 3, 2024 10:21am
Ovid halts preclinical work, IV program after soticlestat fail
Aug 13, 2024 9:15am
Stoke's Dravet syndrome med released of partial clinical hold
Aug 7, 2024 8:54am
Marinus lays off 20% to steady ship after IV seizure med issues
May 8, 2024 9:42am
Stoke's shares up 90% as epilepsy drug cuts convulsive seizures
Mar 26, 2024 9:09am
Neurona knocks out $120M raise a year after layoffs
Feb 8, 2024 8:00am